 The problem of how highly to value bench science is distinct from the general objection to hierarchies of evidence (Bluhm 2005). Even if evidence isn’t treated as inherently rankable in value, one key philosophical objection is that much of the biomedical research world is treated by EBM as less important than clinical patient experiments, or meta-analyses of such experimental data. Solomon explains that this position is in tension with a simultaneous trend in biomedicine, an increased concern with translational medicine (an effort to improve the process of moving candidate treatments from (the laboratory) bench to (the patient’s) bedside (Solomon 2011). This effort to better manage the biomedical research enterprise has brought with it, 